

## DAFTAR PUSTAKA

1. Kementerian Kesehatan Republik Indonesia. Pedoman Nasional Pelayanan Kedokteran Kanker Prostat. 2017; hal 6.
2. Molinier L, Castelli C, Bauvin E, Rebillard X, Soulié M, Daurès JP, *et al.* Cost study of the clinical management of prostate cancer in France: Results on the basis of population-based data. *Eur J Heal Econ.* 2011;12(4):363–71.
3. Sanyal C, Aprikian AG, Chevalier S, Cury FL, Dragomir A. Direct cost for initial management of prostate cancer. *Curr Oncol.* 2013;20(6):522-31.
4. WHO International Agency for Research on Cancer. All Cancers 2018. Global cancer statistics : GLOBOCAN. 2018.
5. Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA A J Clin.* 2018;00(00):1–31.
6. Kimura T, Egawa S. Epidemiology of prostate cancer in Asian countries. *Int J Urol.* 2018;25(6):524–31.
7. Chen R, Ren S, Yiu MK, Fai NC, Cheng WS, Ian LH, *et al.* Prostate cancer in Asia: A collaborative report. *Asian J Urol.* 2014;1(1):15–29.
8. Umbas R, Safriadi F, Mochtar CA, Djatisoesanto W, Hamid ARAH. Urologic cancer in Indonesia. *Jpn J Clin Oncol.* 2015;45(8):708–12.
9. Kementerian Kesehatan Republik Indonesia Pusat Data dan Informasi Kesehatan. Infodatin-Kanker. 2015;hal 4.
10. Wein AJ, Kavoussi LR, Partin AW, Peters CA. *Campbell-Walsh Urology* 11<sup>th</sup> edn. Philadelphia : Elsevier; 2016.
11. Purnomo BB. Dasar – dasar Urologi edisi ketiga. Jakarta : Sagung Seto; 2015.
12. Arcangeli S, Pinzi V, Arcangeli G. Epidemiology of prostate cancer and treatment remarks. *World J Radiol.* 2012;4(6):241.
13. Sun Y-H, Qu M, Ren S-C. Current early diagnostic biomarkers of prostate cancer. *Asian J Androl.* 2014;16(4):549.
14. Alberts AR, Schoots IG, Roobol MJ. Prostate-specific antigen-based prostate cancer screening: Past and future. *Int J Urol.* 2015;22(6):524–32
15. Kim JS, Ryu JG, Kim JW, Hwang EC, Jung S Il, Kang TW, *et al.* Prostate-

- specific antigen fluctuation: What does it mean in diagnosis of prostate cancer?. *Int Braz J Urol.* 2015;41(2):258–64.
16. Ceylan C, Gazel E, Kele B, Doluolu Ö, Yman M. Can the free/total PSA ratio predict the gleason score before prostate biopsy? *Curr Urol.* 2015;9(1):24–7.
  17. Okolo CA, Akinosun OM, Shittu OB, Olapade-Olaopa EO, Okeke LI, Akang EEU, *et al.* Correlation of serum PSA and Gleason score in Nigerian men with prostate cancer. *African J Urol.* 2008;14(1):15–22.
  18. Gurumurthy D, Maggad R, Patel S. Prostate carcinoma: correlation of histopathology with serum prostate specific antigen. *Sci J Clin Med.* 2015;4(4):1-5.
  19. Amarneel S, Gohil MR, Parmar KN, *et al.* Study of Serum Prostate Specific Antigen Level in Prostate Biopsy Specimens. *Int J Of Innovative Research & Development.* 2015;4(6):176–9.
  20. Lojanapiwat B, Anutrakulchai W, Chongruksut W, Udomphot C. Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice. *Prostate Int.* 2014;2(3):133–9.
  21. Jose L, Suma MT, Sadasivan S, *et al.* Gleason's Grading of Carcinoma Prostate with PSA Correlation. *Journal of Medical Science And Clinical Research.* 2017;05(09):27634–9.
  22. Montironi R, Cimadamore A, Cheng L, Lopez-Beltran A, Scarpelli M. Prostate cancer grading in 2018: limitations, implementations, cribriform morphology, and biological markers. *Int J Biol Markers.* 2018;00(0):1 - 4.
  23. Izumi K, Ikeda H, Maolake A, Machioka K, Nohara T, Narimoto K, *et al.* The Relationship Between Prostate-Specific Antigen and TNM Classification or Gleason Score in Prostate Cancer Patients With Low Prostate-Specific Antigen Levels. *The Prostate.* 2015;75(10):1034-1042.
  24. Pai K, Salgaonkar G, Kudva R, Hegde P. Diagnostic Correlation between Serum PSA , Gleason Score and Bone Scan Results in Prostatic Cancer Patients with Bone Metastasi. *British Biomed Bulletin.* 2015;3(01):1–7.
  25. Sanni. 'Hubungan antara kadar Prostate Specific Antigen dengan Gleason Score pada Penderita Adenocarcinoma Prostate'. Medan: Skripsi Universitas

- Sumatera Utara. 2017.
26. McAninch JW, Lue TF. Smith & Tanagho's General Urology, 18<sup>th</sup> edn. California : McGraw Hill. 2013.
  27. Snell RS. Clinical Anatomy By Systems. USA : Lippincott Williams & Wilkins Basic Anatomy. 2007.
  28. Putz.R P, Pabst R. Sobotta : Atlas Anatomi Manusia, edisi 22. Jakarta : EGC. 2007.
  29. Tortora GJ, Derrickson B. Principles of Anatomy and Physiology,12<sup>th</sup> edn. USA : John Wiley & Sons, Inc. 2014.
  30. Hall JE, Guyton AC. Guyton dan Hall Buku Ajar Fisiologi Kedokteran, ed.12. Singapore : Elsevier. 2014.
  31. Sherwood L. Fisiologi Manusia Dari Sel ke Sistem, 6<sup>th</sup> edn. Jakarta : EGC. 2014.
  32. Gartner LP, Hiatt JL. Color Atlas and Text of Histology. Saudi Med J. 2014.
  33. Eroschenko VP. Atlas Histologi di Fiore dengan Korelasi Fungsional, ed.9. Jakarta : EGC. 2003.
  34. Pawlina W, Ross MH. Histology: A Text and Atlas with Correlated Cell and Molecular Biology, 7<sup>th</sup> edn. Netherlands : Wolters Kluwer Health. 2015.
  35. Meschel AL. Histologi Dasar Junqueira Teks & Atlas, ed 12. Jakarta : EGC. 2012.
  36. Marieb EN, Wilhelm PB, Mallatt J. Human Anatomy, 6<sup>th</sup> edn. San Francisco : Pearson Benjamin Cummings. 2012.
  37. World Health Organization. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. 2004.
  38. American Cancer Society. 'Prostate Cancer at a Glance'. 2018. Diakses pada 15 Agustus 2018, tersedia di [https://cancerstatisticscenter.cancer.org/?\\_ga=2.1#!/cancer-site/Prostate](https://cancerstatisticscenter.cancer.org/?_ga=2.1#!/cancer-site/Prostate)
  39. Tewari AK, Whelan P, Graham JD. Prostate Cancer Diagnosis and Clinical Management. USA : John Wiley & Sons. 2014.
  40. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008;15(1):3866–71.

41. Perdana NR, Mochtar CA, Umbas R, Hamid ARAH. The Risk Factors of Prostate Cancer and Its Prevention. Pubmed. 2016;228–38.
42. Leitzmann MF, Rohrmann S. Risk factors for the onset of prostatic cancer : age, location, and behavioral correlates. Dove Press Journal : Clinical Epidemiology. 2012;1–11.
43. Yousefi MS, Rahimi S, Yousefi SM, Hosseini S, Mahabadi AA, Abarqui HF, *et al.* the Incidence , Risk Factors , and Knowledge About the Prostate Cancer Through Worldwide and Iran. World Cancer Research Journal. 2017;4(4):1–8.
44. Aydin M, Bozkurt A, Cikman A, Gulhan B, Karabakan M, Gokce A, *et al.* Lack of evidence of HPV etiology of prostate cancer following radical surgery and higher frequency of the Arg / Pro genotype in turkish men with prostate cancer. International Braz J Urol. 2017;43(1):36–46.
45. Sierra MS, Forman D, Soerjomataram S. Etiology of prostate cancer ( C 61 ) in Central and South America. In: Cancer in Central and South America. Lyon : International Agency for Research on Cancer. 2016;1(1):1–11.
46. Gann PH. Risk Factors for Prostate Cancer. Reviews in Urology. 2002;4(5):3–10.
47. Xu Y, Jiang YF, Wu B. New agonist- and antagonist-based treatment approaches for advanced prostate cancer. J Int Med Res. 2012;40(4):1217–26.
48. Bosland MC. Sex Steroids and Prostate Carcinogenesis Intergrated, Multifactorial Working Hypothesis. NIH Public Access. 2010;1 (0): 1–8.
49. Vogelzang E, Nicholas J, Peter T, William U, Frans MJ, Marston W, *et al.* Comprehensive Textbook of Genitourinary Oncology, 3<sup>rd</sup> edn. USA : Lippincott Williams & Wilkins. 2006.
50. Velcheti V, Karnik S, Bardot SF, Prakash O. Pathogenesis of prostate cancer: lessons from basic research. Ochsner J. 2008;8(4):213–8.
51. Grossmann M, Cheung AS, Zajac JD. Best Practice & Research Clinical Endocrinology & Metabolism Androgens and prostate cancer ; pathogenesis and deprivation therapy. Best Pract Res Clin Endocrinol Metab. 2013;01(1): 1–14.
52. Rizvi MR. Androgen Responsiveness in the Pathophysiology of. Int J Heal Rehabil Sci Vol. 2015;4(2):122–41.



53. Sfanos KS, Isaacs WB, Marzo AM. Infections and inflammation in prostate cancer. 2013;1(1):3–11.
54. Karan D, Dubey S. From Inflammation to Prostate Cancer : The Role of Inflammasomes. 2016;5(1): 1-10.
55. Hughes C, Murphy A, Martin C, Sheils O, Leary JO. Molecular pathology of prostate cancer. 2005;1(2): 673–84.
56. Ulamec M. Inflammation in Prostatic Hyperplasia and Carcinoma—Basic Scientific Approach. 2017;7(04):1–7.
57. Karen S Sfanos AMDM. Prostate cancer and inflammation : the evidance. NIH Public Access. 2012;60(1):199–215.
58. Mustafa M, Salih A, Ilzam E, Sharifa A, Suleiman M, Hussain S. Prostate Cancer: Pathophysiology, Diagnosis, and Prognosis. IOSR J Dent Med Sci Ver II. 2016;15(6):2279–861,
59. Dasgupta P, Kirby RS. ABC of Prostate Cancer 1<sup>st</sup> ed. USA : John Wiley & Sons, Inc. 2011.
60. Hammerich K, Ayala G, Wheeler T. Anatomy of the prostate gland and surgical pathology of prostate cancer. UK : Cambridge University Press. 2008.
61. Beckmann KR, O’Callaghan ME, Ruseckaite R, Kinnear N, Miller C, Evans S, *et al.* Prostate cancer outcomes for men who present with symptoms at diagnosis. BJU Int. 2017;119(6):862–71.
62. Kirakoya B, Hounnasso PP, Pare AK, Mustapha AB, Zango B. Clinico-Pathological Features of Prostate Cancer At the University Hospital Yalgado Ouedraogo, Ouagadougou, Burkina Faso. J West Afr Coll Surg. 2014;4(4):70–81.
63. Young S-M, Bansal P, Vella ET, Finelli A, Levitt C, Loblaw A. Systematic review of clinical features of suspected prostate cancer in primary care. Can Fam physician Médecin Fam Can. 2015;61(1):26-35.
64. Umbas R. Penanganan Kanker Prostat saat ini dan Beberapa Perkembangan Baru. Indonesian Journal of Cancer. 2008;3:114–9.
65. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, *et al.* EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol.

- 2017;71(4):618–29.
66. Zivkovic S. Correlation between prostate-specific antigen and histopathological difference of prostate carcinoma. *Arch Oncol*. 2004;12(3):148–52.
67. Reynard J, Brewster S BS. *Oxford handbook of Urology*. 2013.
68. Rice TW, Gress DM, Patil DT, Hofstetter WL, Kelsen DP, Blackstone EH. Prostate Cancer – Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. *A Cancer J Clin*. 2017;67(4):304–17.
69. Chen F, Zhao X. Prostate Cancer: Current Treatment and Prevention Strategies. *Iran Red Crescent Med J*. 2013;15(4):279–84.
70. Neupane S, Steyerberg E, Raitanen J, Talala K, Pylväläinen J, Taari K, *et al*. Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial. *Int J Urol*. 2017; 25(12): 270 - 76.
71. Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, *et al*. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. *Eur Urol*. 2016;69(3):428–35.
72. Shah RB, Zhou M. Recent advances in prostate cancer pathology: Gleason grading and beyond. *Pathol Int*. 2016;66(5):260–72.
73. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. *Eur Urol*. 2016;70(1):93–105.
74. Kryvenko ON, Epstein JI. Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System. *Arch Pathol Lab Med*. 2016;140(10):1140–52.
75. Huang HQ, Zhang Y, Xu HG. Different free prostate-specific antigen to total prostate-specific antigen ratios using three detecting systems. *J Clin Lab Anal*. 2018;32(2):2016–8.
76. Thristy I. Prostat Spesifik Antigen. *Jurnal FK Muhammadiyah Sumatera Utara*. 2016;3(9):14–6.
77. Akakura Koichiro. Clinical Use of Prostate Specific Antigen (PSA). *Jmaj*. 2004;47(12):549–54.
78. Myh E, Umbas R, Mochtar CA, Santoso RB. Prostate Specific Antigen (PSA)

- Inisial  $\geq 100$  ng/ml Menggambarkan Stadium Lanjut dan Rendahnya *Survival* Kanker Prostat. *Indonesian Journal of Cancer*. 2011;5(2):7–10.
79. Ariani DT, Umbas R. Peran Volume Prostat dan PSA Serum untuk Deteksi Kanker Prostat pada Penderita LUTS Dengan Colok Dubur Normal. *Indonesian Journal of Cancer*. 2011;5(2):5–9.
80. Adhyam M, Gupta AK. A Review on the Clinical Utility of PSA in Cancer Prostate. *Indian J Surg Oncol*. 2012;3(2):120–9.
81. Lima N, Soares D, Rhoden E. Importance of prostate-specific antigen (PSA) as a predictive factor for concordance between the Gleason scores of prostate biopsies and radical prostatectomy specimens. *Clinics*. 2013;68(6):820–4.
82. Moon SJ, Park SY, Lee TY. Predictive factors of Gleason score upgrading in localized and locally advanced prostate cancer diagnosed by prostate biopsy. *Korean J Urol*. 2010;51(10):677–82.
83. Guimaraes MS, Quintal MM, Meirelles LR, Magna LA, Ferreira U, Billis A. Gleason score as predictor of clinicopathologic findings and biochemical (PSA) progression following radical prostatectomy. *Int Braz J Urol*. 2008;34(1):23–9.
84. Heidenreich a, Bolla M, Joniau S, Mason MD, Matveev V, Mottet N, *et al*. Guidelines on Prostate Cancer. Update. *EAU*. 2011;53(2):31–45.
85. Sugiyono. *Metode Penelitian Kuantitatif, Kualitatif, Dan R&D*. Bandung: Alfabeta; 2016.
86. Andreas IM, Alvarino, Hilbertina N. Gambaran Karsinoma Prostat di RSUP Dr. M. Djamil Padang. *Jurnal Kesehatan Andalas*. 2017;6(2):305–10.
87. Solang VR, Monoarfa A, Tjandra F. Profil penderita kanker prostat di RSUP Prof . Dr . R . D . Kandou Manado periode tahun 2013-2015. *J e-Clinic (eCi)*. 2016;4 (2): 1 - 8.
88. Putriyuni A, Hilbertina N. Adenokarsinoma Prostat : Penilaian Prognostik Dan Derajat Histopatologi. 2014. *Jurnal Kesehatan Andalas*. 2017; 37(94):93–100.
89. Khant V, Goswami H, Shah P. Correlation of serum prostate-specific antigen level in various prostate pathology in elderly men. *Int J Med Sci Public Heal*. 2016;6(2):257-61.
90. Zamzami Z, Ph D. Well Responses of Clinical Symptoms and Prostate

- Specific Antigen Follow up in Advanced Stage Prostate Cancer Patients in One Year Managed by Hormonal Therapy. *Int J Of MedSci and ClinInvent*. 2018;5(05):3789–93.
91. Bashir MN. Epidemiology of Prostate Cancer. *Asian Pacific J of Cancer*. 2015;16(2012):5137–41.
92. Bashir MN, Ahmad MR, Malik A. Risk Factors of Prostate Cancer : a Case-control Study in Faisalabad,Pakistan. *Asian Pacific J of Cancer*. 2014;15:10237–40.
93. Dharmojo B, Martono H E. *Buku Ajar Geriatri Ilmu Kesehatan Usia Lanjut*. Semarang: Balai Penerbit Fakultas Kedokteran Universitas Indonesia; 2006.
94. Brawer MK. Androgen supplementation and prostate cancer risk: strategies for pretherapy assessment and monitoring. *Rev Urol*. 2003;5(1): 29-33.
95. Alchin DR, Murphy D, Lawrentschuk N. What are the predictive factors for gleason score upgrade following RP?. *Urol Int*. 2016;96(1):1–4.
96. Huang TH, Kuo JY, Huang YH, Chung HJ, Huang WJS, Wu HHH, *et al*. Prostate cancer in young adults—Seventeen-year clinical experience of a single center. *J Chinese Med Assoc*.2017;80(1):39–43.
97. Nnabugwu II, Udeh EI, Ugwumba FO, Ozoemena FO. Predicting Gleason score using the initial serum total prostate-specific antigen in Black men with symptomatic prostate adenocarcinoma in Nigeria. *Clin Interv Aging*. 2016;11:961–6.
98. Lee DK, Park JH, Kim JH, Lee SJ, Jo MK, Gil MC, *et al*. Progression of prostate cancer despite an extremely low serum level of prostate-specific antigen. *Korean J Urol*. 2010;51(5):358–61.
99. Nishio R, Furuya Y, Nagakawa O, Fuse H. Metastatic prostate cancer with normal level of serum prostate-specific antigen. *Int Urol Nephrol*. 2003;35(2):189–92.
100. Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA, Hitzhusen K, *et al*. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. *Wiley InterScience*. 2007;109(2):198–204.
101. Mahal BA, Aizer AA, Efsthathiou JA, Nguyen PL. Association of very low prostate-specific antigen levels with increased cancer-specific death in men



with high-grade prostate cancer. *Cancer*. Wiley Online Library. 2016;122(1):78–83.

102. Ang M, Rajcic B, Foreman D, Moretti K, O’Callaghan ME. Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL. *BJU Int*. 2016;117:68–75.

103. Jang JY, Kim YS. Is prostate biopsy Essential to Diagnose prostate cancer in the older patient with extremely high prostate-specific antigen? *Korean J Urol*. 2012;53(2):82–6.

